Abstract:Recessive dystrophic epidermolysis bullosa (RDEB) is a rare autosomal inherited skin blistering disorder caused by mutations in the type VII collagen gene (COL7A1). Bonafont et. al. reported an electroporation-based COL7A1 exon 80 deletion strategy for RDEB treatment, which efficiently restored functional type VII collagen (C7) in the RDEB patient keratinocyte cells (RDEBK)ex vivo. Following this strategy, we synthesized and tested a library of hyperbranched aminated polyesters (HAPEs) as gene delivery vectors and developed topical non-viral gene editing therapies for RDEB. The CRISPR/Cas9 machinery was delivered by the selected HAPEs in either an all-in-one plasmid or ribonucleoprotein complex (RNP) to cells. HAPE-D/DNA complexes achieved higher or comparable gene expression (96% positive cells), compared to commercial reagents including LipofectamineTM 3000, XfectTM, jetPEI®, and jetOPTIMUS®. Furthermore, CRISPR/Cas9 plasmid delivered by HAPE-D contributed to around 25% targeted deletion of COL7A1 exon 80 and bulk C7 restoration in RDEBK polyclones, while maintaining good cell viability. The best protein delivery HAPE (HAPE-P) demonstrated great ability on universal protein delivery and successfully delivered cytosolic protein such as bovine serum albumin, immunoglobulin, saporin and β-Galactosidase into HeLa and RDEBK cells. The cytosolic delivered β-Galactosidase had 5 times better enzymatic activity than commercial reagents like PULsin® and Pierce™ Protein Transfection Reagent in HeLa and RDEBK cells (P<0.0001). Complexed with HAPE-P, CRISPR Cas9 RNP introduced 69% indels and 32% targeted exon 80 deletion in human embryonic kidney polyclones. In summary, the newly developed HAPEs in this study can efficiently deliver a CRISPR/Cas9 system in either DNA or ribonucleoprotein format. The non-viral gene editing therapy developed here achieved efficient C7 restoration in RDEBK cells, which has a high potential for use as a topical treatment for RDEB and can be adapted to other diseases.

834 CRISPR/Cas9 Based COL7A1 Genomic Editing in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Via Non-Viral Polymer Delivery System

901 Non-viral Gene Editing Therapy for Recessive Dystrophic Epidermolysis Bullosa: CRISPR/Cas9 Mediated COL7A1 Exon 80 Deletion Strategy

836 Non-viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Using a Highly Branched Poly(β-Amino Ester) Polymer (HPAE-EB)

CRISPR-Cas9-based Non-Viral Gene Editing Therapy for Topical Treatment of Recessive Dystrophic Epidermolysis Bullosa

398 A Simple, Efficient Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Efficient and Robust Highly Branched Poly(β-amino Ester)/minicircle COL7A1 Polymeric Nanoparticles for Gene Delivery to Recessive Dystrophic Epidermolysis Bullosa Keratinocytes

Non-viral Delivery of CRISPR–Cas9 Complexes for Targeted Gene Editing Via a Polymer Delivery System

476 Non-viral Gene Delivery Platform for Topically Treating Rare Genodermatoses

455 Non-viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa: Hyper Branched Aminated Polyesters Mediated Minicircle DNA Delivery

Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa

222 Formulation of a Novel High Performance Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Development of Minicircle Vectors Encoding COL7A1 Gene with Human Promoters for Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa.

200 A Comparison of Minicircle Vectors Expressing COL7A1 under the Control of Human Promoters for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Highly efficient CRISPR/Cas9‐mediated exon skipping for recessive dystrophic epidermolysis bullosa

Highly Branched Poly(β-Amino Ester)s for Gene Delivery in Hereditary Skin Diseases

P07 Optimizing DNA specificity and applicability of base and prime editors on COL7A1 variants causing recessive dystrophic epidermolysis bullosa

An RNA-targeted therapy for dystrophic epidermolysis bullosa

Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa

Preclinical model for phenotypic correction of dystrophic epidermolysis bullosa by in vivo CRISPR-Cas9 delivery using adenoviral vectors

Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model

CRISPR/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells